Telix Pharmaceuticals Appoints Maria Rivas and William Jellison to Board of Directors

On April 9, 2026, Telix Pharmaceuticals Limited announced the appointment of two new Non-Executive Directors, Maria Rivas, MD, and William (Bill) Jellison, effective May 11, 2026. Dr. Rivas brings over 25 years of experience in late-stage clinical development and commercialization, having recently served as Chief Medical Officer at Pfizer. Mr. Jellison is a corporate finance leader with over 30 years of experience, including a former role as CFO of Stryker Corporation. These appointments are part of Telix's strategic board expansion and succession planning as the company evolves as a dual-listed, global commercial-stage biopharmaceutical entity. The additions follow the recent appointment of David Gill and are intended to strengthen the Board's expertise in U.S. public company governance, financial oversight, and clinical leadership. Telix is a radiopharmaceutical company focused on oncology and rare diseases, with headquarters in Melbourne, Australia, and listings on both the ASX and Nasdaq.